远程医疗给予静脉tPA后溶栓后转运与留院治疗结局比较
该回顾性研究纳入17家基层医院经远程医疗接受静脉tPA治疗的430例缺血性卒中患者,其中232例(53.9%)溶栓后转运至中心医院。调整后住院时长、院内死亡与出院去向无显著差异,90天改良Rankin量表评分<2的比例两组亦无差异。
要点
- 溶栓后转运与留院患者在调整后住院时长、院内死亡及出院去向方面无显著差异
- 64%患者有完整90天mRS评分,两组良好结局(mRS<2)比例无差异
- 转运组入院NIHSS评分中位数更高,研究可能对微小差异把握度不足
核心结论
- 在本网络中,经远程医疗接受静脉tPA治疗的溶栓后转运与留院患者各项测量结局无差异,但研究可能对微小差异把握度不足。
主要发现
- 430例中232例(53.9%)溶栓后转运至中心医院,转运组入院NIHSS评分中位数10(四分位距5-18)高于留院组6(四分位距4-10),P<0.001。
- 未调整住院时长留院组更长(发生率比0.82;95%CI 0.71-0.95),调整后住院时长、院内死亡与出院去向无显著差异。
- 64%患者有完整90天mRS评分,良好结局(mRS<2)比例两组无差异。
临床怎么用
- 对于经远程医疗接受静脉tPA治疗的缺血性卒中患者,溶栓后留院或转运至中心医院均可考虑,需结合个体情况决策。
局限性
- 为回顾性研究,仅64%患者有完整90天mRS评分,且研究可能对微小差异把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Telemedicine is increasingly utilized for intravenous tPA (tissue-type plasminogen activator) delivery. The comparative safety of leaving tPA-treated patients at a presenting (spoke) hospital (drip-and-stay) or transferring patients to a central treating (hub) hospital (drip-and-ship) is not established. We sought to compare outcomes between drip-and-ship and drip-and-stay patients treated with tPA via telemedicine. We hypothesized that there would be no differences in short-term outcomes of in-hospital mortality, length of stay, or discharge disposition or in 90-day outcomes between groups. Methods- We retrospectively identified patients treated with tPA at 17 spoke hospitals between September 2015 and December 2016. Demographic, clinical, and outcome data were obtained from a prospective telemedicine registry. We used negative binomial, multinomial, and logistic regression analyses to evaluate length of stay, discharge disposition, and inpatient mortality, respectively. We compared the proportion of patients with 90-day modified Rankin Scale score <2 by group. Results- Among 430 tPA-treated patients, 232 (53.9%) were transferred to the hub after treatment. The median arrival National Institutes of Health Stroke Scale score was higher for drip-and-ship (10; interquartile range, 5-18) compared with drip-and-stay patients (6; interquartile range, 4-10; P<0.001). Unadjusted length of stay was longer in drip-and-stay patients (incidence rate ratio, 0.82; 95% CI, 0.71-0.95). There were no significant differences in adjusted length of stay, hospital mortality, or discharge disposition. Among the 64% of patients with complete 90-day modified Rankin Scale score, the proportion with good outcomes (modified Rankin Scale score <2) did not differ between groups. Conclusions- We found no differences in measured outcomes between drip-and-ship and drip-and-stay patients treated in our network, although our study may be underpowered to detect small differences.
引用
- Wysocki NA, Bambhroliya A, Ankrom C, et al. Outcomes Among Patients With Ischemic Stroke Treated With Intravenous tPA (Tissue-Type Plasminogen Activator) via Telemedicine. Stroke. 2019. PMID: 30852962. doi:10.1161/STROKEAHA.118.024703
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。